AbbVie's acquisition of Cerevel Therapeutics strengthens its neuroscience pipeline with promising candidates, making ABBV a ...

On 30 March, the FDA accepted AbbVie’s new drug application (NDA) for atogepant for the preventive treatment of migraine.

AbbVie's Skyrizi and Rinvoq are rapidly growing, offsetting Humira's revenue decline. Read why ABBV presents a strong ...

The European Medicines Agency said on Tuesday that it has withdrawn the marketing authorisation for Abbvie's hepatitis C drug ...

AbbVie's drug met the main goal in a late-stage trial when tested in patients with early Parkinson's disease, the company ...

今年5月，艾伯维在美国临床肿瘤学会（ASCO）大会口头报告了ABBV-706针对晚期实体瘤患者中的首次人体研究中单药疗法的剂量递增结果。该研究招募了复发/难治性小细胞肺癌（SCLC）患者、中枢神经系统（CNS）肿瘤患者、神经内分泌肿瘤（NEN）。数据显示，对于33例RECIST可评估的患者，确认的客观缓解率（ORR）为21%，其中SCLC患者为40%。未经确认的总体缓解率为45%，其中SCLC患者 ...

AbbVie reported Thursday that its experimental Parkinson’s drug that it got from Cerevel Therapeutics helped alleviate ...

We’re only a few months a way from the end of the year, but pharma companies still have a steady stream of clinical trial ...

While it isn’t clear what triggered the $82 million payment, the announcement comes a week after AbbVie said that its ...

AbbVie (ABBV) stock price has done well this year as it surged to a record high of $200. It has jumped by more than 32% this ...

Leerink Partners analyst David Risinger has maintained their neutral stance on ABBV stock, giving a Hold rating on September 13. David ...

Given its better valuation, we believe that Bristol Myers Squibb stock (NYSE: BMY) is currently a better pick than its peer – ...